美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Pasithea Therapeutics Corp Warrant

0.0137

+0.003230.48%

成交量：328.00

成交额：3.95

市值：10.20万

市盈率：0.00

高：0.0137

开：0.0105

低：0.0105

收：0.0105

52周最高：0.1198

52周最低：0.0100

股本：744.36万

流通股本：744.36万

量比：0.68

换手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-5.2115

净资产收益率：-8.41%

总资产收益率：-10.52%

市净率：0.00

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Pasithea Therapeutics获得ALS协会100万美元资金，研究Pas-004在治疗ALS中的疗效、安全性和耐受性

Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验，取得积极的安全性、药代动力学（Pk）和药效动力学（Pd）数据

Pasithea Therapeutics公布在成人NF1患者中进行的1/1B期试验中Pas-004片剂的积极药代动力学（Pk）数据

Pasithea Therapeutics Corp.宣布在韩国启动Pas-004治疗成人NF1患者的1/1B期临床试验点

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/KTTAW"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KTTAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTAW\",,,,,undefined,":{"symbol":"KTTAW","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp Warrant","latestPrice":0.0137,"timestamp":1770930000000,"preClose":0.0105,"halted":0,"volume":328,"delay":0,"changeRate":0.30476190476190473,"floatShares":7443563,"shares":7443563,"eps":-5.2115,"marketStatus":"盘后交易","change":0.0032,"latestTime":"02-12 17:08:52 EST","open":0.0105,"high":0.0137,"low":0.0105,"amount":3.9457,"amplitude":0.304762,"askPrice":0.0136,"askSize":200,"bidPrice":0.0101,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.2115,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770944400000},"marketStatusCode":4,"adr":0,"listingDate":1631678400000,"exchange":"NASDAQ","adjPreClose":0.0105,"volumeRatio":0.683333},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTAW\",,,,,undefined,":{"symbol":"KTTAW","floatShares":7443563,"roa":"-10.52%","roe":"-8.41%","lyrEps":0,"volumeRatio":0.683333,"shares":7443563,"dividePrice":0,"high":0.0137,"amplitude":0.304762,"preClose":0.0105,"low":0.0105,"week52Low":0.01,"pbRate":"0.00","psRate":"2.41","week52High":0.1198,"institutionHeld":0,"latestPrice":0.0137,"committee":-0.333333,"eps":-5.2115,"divideRate":0,"volume":328,"delay":0,"ttmEps":-5.2115,"open":0.0105,"prevYearClose":0.0141,"prevWeekClose":0.0105,"prevMonthClose":0.0142,"prevQuarterClose":0.0141,"fiveDayClose":0.012,"twentyDayClose":0.011,"sixtyDayClose":0.0188},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTAW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTAW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTAW\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1167809601","title":"Pasithea Therapeutics获得ALS协会100万美元资金，研究Pas-004在治疗ALS中的疗效、安全性和耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1167809601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167809601?lang=zh_cn&edition=fundamental","pubTime":"2025-11-25 20:02","pubTimestamp":1764072154,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics获得ALS协会100万美元资金，用于研究Pas-004在治疗肌萎缩侧索硬化症（ALS）中的疗效、安全性和耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTAW","KTTA","BK4139"],"gpt_icon":0},{"id":"1111694989","title":"Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验，取得积极的安全性、药代动力学（Pk）和药效动力学（Pd）数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1111694989","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111694989?lang=zh_cn&edition=fundamental","pubTime":"2025-11-24 20:02","pubTimestamp":1763985763,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验，取得积极的安全性、药代动力学（Pk）和药效动力学（Pd）数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTAW","KTTA","BK4139"],"gpt_icon":0},{"id":"1179978808","title":"Pasithea Therapeutics公布在成人NF1患者中进行的1/1B期试验中Pas-004片剂的积极药代动力学（Pk）数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1179978808","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179978808?lang=zh_cn&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746513,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics公布在成人NF1患者中进行的1/1B期试验中Pas-004片剂的积极药代动力学（Pk）数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139","KTTAW"],"gpt_icon":0},{"id":"1126813537","title":"Pasithea Therapeutics Corp.宣布在韩国启动Pas-004治疗成人NF1患者的1/1B期临床试验点","url":"https://stock-news.laohu8.com/highlight/detail?id=1126813537","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126813537?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 19:03","pubTimestamp":1758020605,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp.宣布在韩国启动临床试验点，用于开展Pas-004药物治疗成人NF1患者的1/1B期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTAW","KTTA"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/KTTAW\",params:#limit:6,delay:false,,,undefined,":[]}}